{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:06:09Z","timestamp":1792677969013,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>Pro re nata<\/jats:italic> (PRN) medication is used \u201cas needed\u201d for symptoms such as agitation and insomnia, in addition to regular daily pharmacotherapy of mental disorders. However, there is no high-quality evidence on the effectiveness of psychotropic PRN medications and concerns have been raised about their potential to contribute to polypharmacy. This study introduced a psychotropic PRN prescription-monitoring programme for psychiatric inpatients with the aim of examining the change before and after the implementation of the programme.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>This study included 389 patients admitted to the psychiatric department between 1 July 2021 and 30 June 2023. The psychotropic PRN prescription-monitoring programme was implemented in July 2022, and the participants were classified into monitoring and non-monitoring groups. Demographic data (age, sex, and diagnosis), regular prescriptions before admission and at discharge, psychotropic PRN prescriptions before admission and at discharge, and the total number of psychotropic PRN prescriptions during hospitalisation were compared between the two groups. Data on psychotropic prescription were collected by psychotropic category. The significance level of 5% was set at 1.67\u2009\u00d7\u200910<jats:sup>\u22123<\/jats:sup> using the Bonferroni correction for multiple testing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The psychotropic PRN prescription <jats:italic>ratio<\/jats:italic> at discharge in the monitoring group was 9.3%, which was significantly lower than the 28.1% in the non-monitoring group. The percentage of patients with a PRN prescription during hospitalisation in the monitoring group was 29.8%, which was significantly lower than the 64.5% in the non-monitoring group. In the non-monitoring group, there was no statistically significant difference in the number of psychotropic drugs prescribed regularly before and after admission. However, in the monitoring group, the number of psychotropic drugs in the regular prescriptions at discharge was 1.87\u2009\u00b1\u20091.24, which was significantly lower than 2.47\u2009\u00b1\u20091.90 in the regular prescription before admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings suggest that a psychotropic PRN prescription-monitoring programme may contribute to the elimination of polypharmacy, including regular prescriptions. Further research is required to optimise psychotropic PRN prescriptions and reduce polypharmacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-025-06508-w","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T13:25:49Z","timestamp":1737120349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of psychotropic pro re nata prescription-monitoring programme on prescriptions for inpatients with psychiatric disorders: a retrospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Tanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tobita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"6508_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. The American Psychiatric Association Practice Guideline for The Treatment of Patients With Schizophrenia, third Edition. Washington D.C: American Psychiatric Association; 2021.","DOI":"10.1176\/appi.books.9780890424841"},{"key":"6508_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/npr2.12193","volume":"41","author":"Japanese Society of Neuropsychopharmacology","year":"2021","unstructured":"Japanese Society of Neuropsychopharmacology. Guideline for pharmacological therapy of schizophrenia. Neuropsychopharmacol Rep. 2021;41:266\u2013324. https:\/\/doi.org\/10.1002\/npr2.12193.","journal-title":"Neuropsychopharmacol Rep"},{"key":"6508_CR3","unstructured":"American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, third edition. Washington D.C: American Psychiatric Association; 2010."},{"key":"6508_CR4","first-page":"1159","volume":"64","author":"K Ogasawara","year":"2012","unstructured":"Ogasawara K. Ozaki N [Review of the new treatment guideline for major depressive disorder by the Japanese Society of Mood Disorders]. Brain Nerve. 2012;64:1159\u201365.","journal-title":"Brain Nerve"},{"key":"6508_CR5","doi-asserted-by":"crossref","unstructured":"Higuchi T. Major depressive disorder treatment guidelines in Japan. J Clin Psychiatry. 2010;71;Suppl E1:e05.","DOI":"10.4088\/JCP.9058se1c.05gry"},{"key":"6508_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/pcn.13349","volume":"76","author":"H Baba","year":"2022","unstructured":"Baba H, Kito S, Nukariya K, Takeshima M, Fujise N, Iga J, et al. Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese Society of mood disorders. Psychiatry Clin Neurosci. 2022;76:222\u201334.","journal-title":"Psychiatry Clin Neurosci"},{"key":"6508_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/npr2.12122","volume":"40","author":"K Ichihashi","year":"2020","unstructured":"Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, et al. Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of \u201cEffectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)\u201d project. Neuropsychopharmacol Rep. 2020;40:281\u20136. https:\/\/doi.org\/10.1002\/npr2.12122.","journal-title":"Neuropsychopharmacol Rep"},{"key":"6508_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/pcn.13143","volume":"74","author":"H Iida","year":"2020","unstructured":"Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, et al. Unmet needs of patients with major depressive disorder - Findings from the \u201cEffectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)\u201d project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci. 2020;74:667\u20139. https:\/\/doi.org\/10.1111\/pcn.13143.","journal-title":"Psychiatry Clin Neurosci"},{"key":"6508_CR9","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1111\/bcp.13369","volume":"83","author":"J Brett","year":"2017","unstructured":"Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, Nassir A, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: A descriptive cohort study. Br J Clin Pharmacol. 2017;83:2581\u20138. https:\/\/doi.org\/10.1111\/bcp.13369.","journal-title":"Br J Clin Pharmacol"},{"key":"6508_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00406-021-01358-5","volume":"272","author":"HH Stassen","year":"2022","unstructured":"Stassen HH, Bachmann S, Bridler R, Cattapan K, Herzig D, Schneeberger A, et al. Detailing the effects of polypharmacy in psychiatry: Longitudinal study of 320 patients hospitalized for depression or schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022;272:603\u201319. https:\/\/doi.org\/10.1007\/s00406-021-01358-5.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"21","key":"6508_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.9758\/cpn.2023.21.2.332","volume":"30","author":"Y Kyou","year":"2023","unstructured":"Kyou Y, Oishi S, Takizawa T, Yoshimura Y, Hashimoto I, Suzuki R, et al. Influence of psychotropic pro re nata drug use on outcomes in hospitalized patients with schizophrenia. Clin Psychopharmacol Neurosci. 2023;30(21):332\u20139. https:\/\/doi.org\/10.9758\/cpn.2023.21.2.332.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"6508_CR12","doi-asserted-by":"publisher","first-page":"103007","DOI":"10.1016\/j.ajp.2022.103007","volume":"69","author":"K Ichihashi","year":"2022","unstructured":"Ichihashi K, Kyou Y, Hasegawa N, Yasui-Furukori N, Shimizu Y, Hori H, et al. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. Asian J Psychiatr. 2022;69:103007. https:\/\/doi.org\/10.1016\/j.ajp.2022.103007.","journal-title":"Asian J Psychiatr"},{"key":"6508_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/pcn.12056","volume":"67","author":"J Fujita","year":"2013","unstructured":"Fujita J, Nishida A, Sakata M, Noda T, Ito H. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia. Psychiatry Clin Neurosci. 2013;67:345\u201351. https:\/\/doi.org\/10.1111\/pcn.12056.","journal-title":"Psychiatry Clin Neurosci"},{"key":"6508_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2702.2007.02236.x","volume":"17","author":"JA Baker","year":"2008","unstructured":"Baker JA, Lovell K, Harris N. A best-evidence synthesis review of the administration of psychotropic pro re nata (PRN) medication in inpatient mental health settings. J Clin Nurs. 2008;17:1122\u201331. https:\/\/doi.org\/10.1111\/j.1365-2702.2007.02236.x.","journal-title":"J Clin Nurs"},{"key":"6508_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/inm.12265","volume":"26","author":"K Martin","year":"2017","unstructured":"Martin K, Arora V, Fischler I, Tremblay R. Descriptive analysis of pro re nata medication use at a Canadian psychiatric hospital. Int J Ment Health Nurs. 2017;26:402\u20138. https:\/\/doi.org\/10.1111\/inm.12265.","journal-title":"Int J Ment Health Nurs"},{"key":"6508_CR16","doi-asserted-by":"publisher","unstructured":"Douglas-Hall P, Whicher EV. 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev. 2015;2015:CD003441. https:\/\/doi.org\/10.1002\/14651858.CD003441.pub3.","DOI":"10.1002\/14651858.CD003441.pub3"},{"issue":"6","key":"6508_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","volume":"26","author":"D Riemann","year":"2017","unstructured":"Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675\u2013700. https:\/\/doi.org\/10.1111\/jsr.12594.","journal-title":"J Sleep Res"},{"key":"6508_CR18","doi-asserted-by":"publisher","unstructured":"Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24(2):79\u2013117. https:\/\/doi.org\/10.1080\/15622975.2022.2086295.","DOI":"10.1080\/15622975.2022.2086295"},{"key":"6508_CR19","doi-asserted-by":"publisher","unstructured":"Kato T, Ogasawara K, Motomura K, Kato M, Tanaka T, Takaesu Y, et al; JSMD Bipolar Disorder Guidelines Revision Working Group; JSMD Bipolar Disorder Committee; JSMD Guidelines Committee. Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders). Psychiatry Clin Neurosci. 2024;78(11):633\u2013645. https:\/\/doi.org\/10.1111\/pcn.13724","DOI":"10.1111\/pcn.13724"},{"key":"6508_CR20","unstructured":"National Institute for Health and Care Excellence, author. Violence and aggression: Short-term management in mental health, health and community settings. National Institute for Health and Care Excellence; 2015. May 28. https:\/\/www.nice.org.uk\/guidance\/ng10. Accessed at 2024 August 30."},{"key":"6508_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/inm.12306","volume":"27","author":"L Barr","year":"2018","unstructured":"Barr L, Wynaden D, Heslop K. Nurses\u2019 attitudes towards the use of PRN psychotropic medications in acute and forensic mental health settings. Int J Ment Health Nurs. 2018;27:168\u201377. https:\/\/doi.org\/10.1111\/inm.12306.","journal-title":"Int J Ment Health Nurs"},{"issue":"3","key":"6508_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/00912174231177230","volume":"59","author":"S Schr\u00f6der","year":"2024","unstructured":"Schr\u00f6der S, Schulze Westhoff M, Pfister T, Bleich S, Wedeg\u00e4rtner F, et al. Characteristics of clinical-pharmacological recommendations in psychiatry in Germany. Int J Psychiatry Med. 2024;59(3):393\u2013405. https:\/\/doi.org\/10.1177\/00912174231177230.","journal-title":"Int J Psychiatry Med"},{"key":"6508_CR23","doi-asserted-by":"publisher","unstructured":"G\u00f6ren JL, Beck SE, Mills BJ, Shtasel DL, Dufresne RL. Development and delivery of a quality improvement program to reduce antipsychotic polytherapy. J Manag Care Pharm. 2010;16(6):393\u2013401. https:\/\/doi.org\/10.18553\/jmcp.2010.16.6.393.","DOI":"10.18553\/jmcp.2010.16.6.393"},{"issue":"2","key":"6508_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2478\/gp-2019-0013","volume":"2","author":"M Stuhec","year":"2019","unstructured":"Stuhec M, Gorenc K. Positive impact of clinical pharmacist interventions on antipsychotic use in patients on excessive polypharmacy evidenced in a retrospective cohort study. Global Psychiatry. 2019;2(2):155\u201364. https:\/\/doi.org\/10.2478\/gp-2019-0013.","journal-title":"Global Psychiatry"},{"issue":"1","key":"6508_CR25","doi-asserted-by":"publisher","first-page":"13641","DOI":"10.1038\/s41598-021-92909-2","volume":"11","author":"M Stuhec","year":"2021","unstructured":"Stuhec M, Tement V. Positive evidence for clinical pharmacist interventions during interdisciplinary rounding at a psychiatric hospital. Sci Rep. 2021;11(1):13641. https:\/\/doi.org\/10.1038\/s41598-021-92909-2.","journal-title":"Sci Rep"},{"issue":"5","key":"6508_CR26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s11096-023-01643-4","volume":"45","author":"M Stuhec","year":"2023","unstructured":"Stuhec M, Hahn M, Taskova I, Bayraktar I, Fitzgerald I, Molitschnig L, Tatarevi\u0107 A, Lindner N, Agnoletto L, da Costa FA. Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health. Int J Clin Pharm. 2023;45(5):1286\u201392. https:\/\/doi.org\/10.1007\/s11096-023-01643-4.","journal-title":"Int J Clin Pharm"},{"issue":"21","key":"6508_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12991-022-00429-8","volume":"26","author":"Y Kyou","year":"2022","unstructured":"Kyou Y, Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, et al. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the \u201cEffectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)\u201d project. Ann Gen Psychiatry. 2022;26(21):52. https:\/\/doi.org\/10.1186\/s12991-022-00429-8.","journal-title":"Ann Gen Psychiatry"},{"key":"6508_CR28","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Arlington: American Psychiatric Association Publishing; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"6508_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.11124\/JBISRIR-2016-003167","volume":"14","author":"B Morkunas","year":"2016","unstructured":"Morkunas B, Porritt K, Stephenson M. Experiences of mental health professionals and patients in the use of pro re nata medication in acute adult mental healthcare settings: A systematic review. JBI Database System Rev Implement Rep Rev Implement Rep. 2016;14:209\u201350. https:\/\/doi.org\/10.11124\/JBISRIR-2016-003167.","journal-title":"JBI Database System Rev Implement Rep Rev Implement Rep"},{"key":"6508_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/01612840.2018.1543739","volume":"40","author":"M Jimu","year":"2019","unstructured":"Jimu M, Doyle L. The Administration of pro re nata Medication by Mental Health Nurses: A Thematic Analysis. Issues Ment Health Nurs. 2019;40:511\u20137. https:\/\/doi.org\/10.1080\/01612840.2018.1543739.","journal-title":"Issues Ment Health Nurs"},{"key":"6508_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/inm.12136","volume":"24","author":"N Hallett","year":"2015","unstructured":"Hallett N, Dickens GL. De-escalation: A survey of clinical staff in a secure mental health inpatient service. Int J Ment Health Nurs. 2015;24:324\u201333. https:\/\/doi.org\/10.1111\/inm.12136.","journal-title":"Int J Ment Health Nurs"},{"key":"6508_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2648.2006.04016.x","volume":"56","author":"JA Baker","year":"2006","unstructured":"Baker JA, Lovell K, Easton K, Harris N. Service users\u2019 experiences of \u201cas needed\u201d psychotropic medications in acute mental healthcare settings. J Adv Nurs. 2006;56:354\u201362. https:\/\/doi.org\/10.1111\/j.1365-2648.2006.04016.x.","journal-title":"J Adv Nurs"},{"key":"6508_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1447-0349.2012.00814.x","volume":"21","author":"M Cleary","year":"2012","unstructured":"Cleary M, Horsfall J, Jackson D, O\u2019Hara-Aarons M, Hunt GE. Patients\u2019 views and experiences of pro re nata medication in acute mental health settings. Int J Ment Health Nurs. 2012;21:533\u20139. https:\/\/doi.org\/10.1111\/j.1447-0349.2012.00814.x.","journal-title":"Int J Ment Health Nurs"},{"key":"6508_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/inm.12427","volume":"27","author":"K Hipp","year":"2018","unstructured":"Hipp K, Kuosmanen L, Repo-Tiihonen E, Leinonen M, Louheranta O, Kangasniemi M. Patient participation in pro re nata medication in psychiatric inpatient settings: An integrative review. Int J Ment Health Nurs. 2018;27:536\u201354. https:\/\/doi.org\/10.1111\/inm.12427.","journal-title":"Int J Ment Health Nurs"},{"key":"6508_CR35","doi-asserted-by":"publisher","unstructured":"Friedman R, Nurenberg JR, Birnbaum S, Schleifer SJ. Using structured clinical feedback to encourage alternatives to use of \"P.R.N.\" medication in a state psychiatric hospital. J Psychiatr Pract. 2012;18(5):381\u20137. https:\/\/doi.org\/10.1097\/01.pra.0000419823.69914.c7.","DOI":"10.1097\/01.pra.0000419823.69914.c7"},{"key":"6508_CR36","doi-asserted-by":"publisher","unstructured":"Smith GM, Davis RH, Altenor A, Tran DP, Wolfe KL, Deegan JA, et al. Psychiatric use of unscheduled medications in the Pennsylvania state hospital system: effects of discontinuing the use of P.R.N. orders. Community Ment Health J. 2008;44(4):261\u201370. https:\/\/doi.org\/10.1007\/s10597-008-9126-y.","DOI":"10.1007\/s10597-008-9126-y"},{"issue":"3","key":"6508_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1176\/appi.ps.201400185","volume":"66","author":"GM Smith","year":"2015","unstructured":"Smith GM, Ashbridge DM, Davis RH, Steinmetz W. Correlation between reduction of seclusion and restraint and assaults by patients in Pennsylvania\u2019s state hospitals. Psychiatr Serv. 2015;66(3):303\u20139. https:\/\/doi.org\/10.1176\/appi.ps.201400185.","journal-title":"Psychiatr Serv"},{"issue":"13","key":"6508_CR38","doi-asserted-by":"publisher","first-page":"759998","DOI":"10.3389\/fphar.2022.759998","volume":"12","author":"A Mardani","year":"2022","unstructured":"Mardani A, Paal P, Weck C, Jamshed S, Vaismoradi M. Practical considerations of PRN medicines management: An integrative systematic review. Front Pharmacol. 2022;12(13):759998. https:\/\/doi.org\/10.3389\/fphar.2022.759998.","journal-title":"Front Pharmacol"},{"key":"6508_CR39","doi-asserted-by":"publisher","unstructured":"Picton L, Ilom\u00e4ki J, Keen CS, Lalic S, Adams B, Clinnick LM, et al. Rates of PRN Medication Administration in Australian residential aged care. In: J Am Med Dir Assoc. 2021;22:117\u2013123.e1. https:\/\/doi.org\/10.1016\/j.jamda.2020.04.033.","DOI":"10.1016\/j.jamda.2020.04.033"},{"issue":"6","key":"6508_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/pharmacy6030095","volume":"29","author":"M Vaismoradi","year":"2018","unstructured":"Vaismoradi M, Amaniyan S, Jordan S. Patient safety and pro re nata prescription and administration: A Systematic Review. Pharmacy (Basel). 2018;29(6):95. https:\/\/doi.org\/10.3390\/pharmacy6030095.","journal-title":"Pharmacy (Basel)"},{"key":"6508_CR41","unstructured":"Ministry of Health, Labour and Welfare. Medical fee revision (in Japanese). https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000106602.html. Accessed at 2024 August 30."},{"key":"6508_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00127-021-02147-0","volume":"57","author":"Y Okada","year":"2022","unstructured":"Okada Y, Akazawa M. Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: An interrupted time-series analysis. Soc Psychiatry Psychiatr Epidemiol. 2022;57:411\u201322. https:\/\/doi.org\/10.1007\/s00127-021-02147-0.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06508-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T13:25:56Z","timestamp":1737120356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6508"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06508-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kitasato University Hospital (approval no. B23-074, date of approval: 27 September 2023) and conducted in accordance with the Declaration of Helsinki. As this was a retrospective observational study using existing medical information, the need for signed informed consent from the patients was waived by the Kitasato University Hospital Ethics Committee. Patients were informed about the purpose and procedures of the study and were given the option to opt-out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hiroyuki Muraoka received honoraria from Eisai, Merck, Otsuka, Meiji Seika, Yoshitomi Pharmaceuticals, Sumitomo Pharma, Viatris, Janssen, Takeda Pharmaceuticals, Lundbeck, Japan, and KYOWA Pharmaceutical Industry. Satoru Oishi has received honoraria from Otsuka, Meiji Seika Pharma, Astellas Pharma, Towa Pharmaceuticals, Yoshitomi Pharmaceutical Industries, Sumitomo Pharma, and Viatris. Taiyo Nishikawa has received an honorarium from Sumitomo Pharma. Ken Inada received personal fees from Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, MSD, Nipro, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Pharma, Yoshitomiyakuhin, and Viatris, and he received research grant support from Mochida and Sumitomo Pharma. Other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"46"}}